

RECEIVED  
CENTRAL FAX CENTER

JUN 27 2007

## AMENDMENTS TO THE CLAIMS

**LISTING OF THE CLAIMS:**

The listing of the claims below replaces all prior versions of the claims.

What is claimed is:

1. (Currently amended) A composition for treating a dermatological inflammatory response, comprising:
  - from about 1.8% to about 9.0% glycerin;
  - from about 0.02% to about 0.08% disodium EDTA;
  - from about 0.04% to about 0.20% sodium lauryl sulfate;
  - from about 0.015% to about 0.20% sodium citrate;
  - from about 0.01% to about 0.019% zinc chloride; and
  - from about 0.5% to about 3% oxidant.
2. (Original) The composition of claim 1, wherein the EDTA, the sodium lauryl sulfate, and the sodium citrate are mixed in an aqueous solution in an acidic pH range of from about 3.5 to about 4.5.
3. (Original) The composition of claim 1, further comprising from about 0.01% to about 0.02% citric acid.
4. (Original) The composition of claim 1, further comprising from about 3.6% to about 4.0% glycerin.
5. (Original) The composition of claim 1, wherein the oxidant is hydrogen peroxide.
6. (Original) The composition of claim 5, wherein the oxidant is 3% hydrogen peroxide.
7. (Currently amended) A composition for treating a dermatological inflammatory response, comprising:
  - from about 1.8% to about 9.0% glycerin;
  - from about 0.05% to about 0.06% disodium EDTA;

from about 0.07% to about 0.08% sodium lauryl sulfate;  
from about 0.015% to about 0.80% zinc chloride;  
from about 0.02% to about 0.03% sodium citrate; and  
from about 1.8% to about 2.1% oxidant.

8. (Original) The composition of claim 7, wherein the ETDA, the sodium lauryl sulfate, and the sodium citrate are mixed in an aqueous solution in an acidic pH range of from about 3.5 to about 4.5.

9. (Original) The composition of claim 8, wherein the oxidant is hydrogen peroxide.

10. (Original) The composition of claim 9, wherein the zinc chloride further comprises from about 0.01% to about 0.02% zinc chloride.

11. (Original) The composition of claim 7, further comprising from about 0.01% to about 0.02% citric acid.

12. (Currently amended) A method of preparing a composition for treating a dermatological inflammatory response, comprising:

dissolving disodium EDTA in deionized water to prepare a solution;  
adding glycerin, sodium lauryl sulfate and sodium citrate to the solution;  
incubating the solution for about 5-10 minutes so that heat dissipates;  
adding citric acid and zinc chloride to the solution;  
incubating the solution for about 5-10 minutes so that heat dissipates;  
mixing the solution for about 30-60 minutes;  
incubating the solution for a minimum of 4 hours;  
adding an oxidant to the solution; and  
mixing the solution for about 30-45 minutes.

13. (Original) The method of claim 12, wherein adding an oxidant further comprises adding hydrogen peroxide.

14. (Currently amended) A composition for treating a dermatological inflammatory response as prepared in claim 13, wherein the composition further comprises,

RECEIVED  
CENTRAL FAX CENTER

JUN 27 2007

about 3.64% glycerin;

about 0.053% disodium EDTA;

about 0.077% sodium lauryl sulfate;

about 0.019% zinc chloride;

about 0.029% sodium citrate; and

about 1.9% oxidant.

15. (Currently amended) A method of treating a dermatological inflammatory response, comprising:

providing a composition having:

from about 1.8% to about 9.0% glycerin;

from about 0.05% to about 0.06% disodium EDTA;

from about 0.07% to about 0.08% sodium lauryl sulfate;

from about 0.01% to about 0.02% zinc chloride;

from about 0.02% to about 0.03% sodium citrate;

from about 1.8% to about 2.1% oxidant; and

applying the composition to an area of a body having the dermatological inflammatory response.

16. (Original) The method of claim 15, wherein applying the composition further comprises applying the composition at least one time daily.

17. (Original) The method of claim 15, wherein applying the composition further comprises applying the composition at a frequency of from 3 to 5 times per day.

18. (Original) The method of claim 17, wherein applying the composition further comprises applying the composition while the dermatological inflammatory response is present.

19.-20. (Canceled)

21. (New) The composition of any one of claims 1, 7, and 14, further comprising an alcohol pre-mix, wherein the alcohol pre-mix comprises alcohol SB38, menthol, peppermint oil, and poloxamer 407.

22. (New) The composition of claim 21, wherein the alcohol pre-mix further includes pluronic F-127.

23. (New) The method of claim 12, wherein the composition further comprises an alcohol pre-mix, wherein the alcohol pre-mix comprises alcohol SB38, menthol, peppermint oil, and poloxamer 407.

24. (New) The method of claim 23, wherein the alcohol pre-mix further includes pluronic F-127.

25. (New) The method of claim 15, wherein the composition further comprises an alcohol pre-mix, wherein the alcohol pre-mix comprises alcohol SB38, menthol, peppermint oil, and poloxamer 407.

26. (New) The method of claim 26, wherein the alcohol pre-mix further includes pluronic F-127.